Log in
Enquire now
‌

US Patent 7811757 Methods for disease detection

Patent 7811757 was granted and assigned to Genzyme on October, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Genzyme
Genzyme
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
78117570
Patent Inventor Names
Anthony P. Shuber0
Date of Patent
October 12, 2010
0
Patent Application Number
115178080
Date Filed
September 7, 2006
0
Patent Citations Received
‌
US Patent 12116624 Systems and methods to detect rare mutations and copy number variation
0
0
0
‌
US Patent 12094573 Methods for multi-resolution analysis of cell-free nucleic acids
0
‌
US Patent 12110560 Methods for monitoring residual disease
0
‌
US Patent 11667967 Methods and systems for detecting genetic variants
0
‌
US Patent 11667959 Systems and methods to detect rare mutations and copy number variation
0
‌
US Patent 11767555 Methods and systems for detecting genetic variants
...
Patent Primary Examiner
‌
Suryaprabha Chunduru
0
Patent abstract

The present invention provides methods for detecting disease by analysis of a patient sample to determine the integrity of nucleic acids in the sample.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7811757 Methods for disease detection

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.